PSAMRIS for individual MRI features as assessed by PSAMRIS-H and PSAMRIS-F, for both treatment arms, at baseline and change from baseline to week 24
| PSAMRIS features | MCP/MTP | PIP | DIP | |||||||||
| GLM+MTX | PLB+MTX | GLM+MTX | PLB+MTX | GLM+MTX | PLB+MTX | |||||||
| Baseline | Change | Baseline | Change | Baseline | Change | Baseline | Change | Baseline | Change | Baseline | Change | |
| Synovitis, mean | 3.8 | −2.87 | 3.44 | −1.94 | 1.93 | −1.54* | 1.06 | 0 | 1 | −0.67 | 1 | −0.71 |
| (observed range) | (0 to 12) | (−9 to 0) | (0 to 7) | (−7 to 2) | (0 to 4) | (−4 to 1) | (0 to 3) | (−3 to 3) | (0 to 3) | (−2 to 0) | (0 to 4) | (-2 to 0) |
| Flexor tenosynovitis, mean | 0.56 | −0.38 | 0.47 | −0.05 | 0.56 | −0.38 | 0.47 | −0.05 | 1.4 | −1 | 1 | −0.33 |
| (observed range) | (0 to 3) | (−2 to 0) | (0 to 3) | (−2 to 2) | (0 to 3) | (−2 to 0) | (0 to 3) | (−2 to 2) | (0 to 3) | (−2 to 0) | (0 to 3) | (-2 to 2) |
| Periarticular inflammation, mean | 3.14 | −1.86 | 3 | −2.41 | 0.33 | 0 | 0.33 | 0.14 | 0.6 | −0.4 | 0.5 | −0.29 |
| (observed range) | (0 to 24) | (−14 to 0) | (0 to 7) | (−7 to 0) | (0 to 2) | (0 to 0) | (0 to 2) | (0 to 1) | (0 to 2) | (−1 to 0) | (0 to 2) | (-1 to 0) |
| Bone marrow oedema, mean | 4.56 | −2.94 | 3.11 | −2.67 | 4.82 | −3.59 | 3 | −0.72 | 1.33 | −1 | 2 | -1 |
| (observed range) | (0 to 23) | (−14 to 0) | (0 to 16) | (−16 to 0) | (0 to 24) | (−22 to 1) | (0 to 16) | (−8 to 4) | (0 to 6) | (−6 to 0) | (0 to 8) | (-4 to 0) |
| Bone erosion, mean | 2.06 | 0.5 | 1.47 | −0.06 | 1.47 | 0 | 1.53 | 0.89 | 6.33 | 0 | 2.89 | 0 |
| (observed range) | (0 to 12) | (−3 to 12) | (0 to 8) | (−2 to 1) | (0 to 13) | (0 to 0) | (0 to 14) | (−1 to 10) | (0 to 14) | (0 to 0) | (0 to 8) | (0 to 0) |
| Bone proliferation, mean | 2.83 | 0 | 1.67 | 0 | 2.67 | 0 | 2.67 | 0 | 2.2 | −0.8 | 2 | 0 |
| (observed range) | (0 to 5) | (0 to 0) | (0 to 5) | (0 to 0) | (0 to 5) | (0 to 0) | (0 to 5) | (0 to 0) | (0 to 4) | (−4 to 0) | (0 to 4) | (0 to 0) |
*Difference between treatment groups in the change from baseline to week 24 (p=0.0054); p<0.05.
DIP, distal interphalangeal joints; GLM, golimumab; MCP/MTP, metacarpal/metatarsophalangeal joints; MTX, methotrexate; PIP, proximal interphalangeal joints; PLB, placebo; PSAMRIS, Psoriatic Arthritis MRI Score; PSAMRIS-F, Psoriatic Arthritis MRI Score for the foot.; PSAMRIS-H, Psoriatic Arthritis MRI Score for the hand.